The Effects of Oral Valiltramiprosate on Plasma p-tau217 and p-Tau217/Aβ42 Ratio in APOE4/4 Homozygotes and their Correlations to Clincial and Imaging Outcomes: Results of Phase 3 APOLLOE4 Clinical Trial in Early AD

valiltramiprosate (ALZ-801) - Alzheon

https://www.ctad-alzheimer.com/sites/www.ctad-alzheimer.com/files/medias/documents/Poster-list_July7.pdf

John HEY 1; Susan ABUSHAKRA 1; Fanny ELAHI 2; Earvin LIANG 1; Patrick KESSLAK 1; Jeremy YU 1; Brian ROTH 1; Susan FLINT 1; Adem ALBAYRAK 1; Elitza HRISTOVA 1; Aidan POWER 1; Martin TOLAR 1

Aug 3, 2026